Skip to main content
S&P 5007,722.60+0.60%DOW52,377.57+0.03%NASDAQ26,477.81+1.18%BTC$80,626.00+0.68%ETH$2,336.46+0.45%GOLD$4,067.50-0.17%OIL$101.92+2.02%
Smart Investors Daily
SID Premium
NT

NASDAQ · NTHI

NEONC TECHNOLOGIES HOLDINGS, INC.

Healthcare · Biotechnology

$3.00

Up+$0.18 (+6.38%)

Updated Oct 28, 2026, 1:09 PM

SID Score

2.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
181.31M
P/E ratio
-3.28
Dividend yield
0.00%
52-week range
$2.50 – $12.00
Volume
69.92K
Avg. volume
77.82K

Price performance · NTHI

NTHI price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 27, 2026

NTHI closed at $3.00 after 21 trading sessions, down 9.09% for the selected period.

Last close
$3.00
Period change
-9.09%
Period low
$2.53
Period high
$3.41
Daily close
View OHLC price history
NTHI OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 27, 2026$2.80$3.00$2.787$3.0069.92K
Oct 26, 2026$3.27$3.62$2.77$2.82235.53K
Oct 23, 2026$2.95$3.55$2.9001$3.27380.85K
Oct 22, 2026$3.00$3.03$2.9101$2.9570.45K
Oct 21, 2026$2.80$2.96$2.7501$2.90106.24K
Oct 20, 2026$2.77$2.93$2.75$2.77102.34K
Oct 19, 2026$2.74$2.8988$2.694$2.72112.95K
Oct 16, 2026$2.80$2.84$2.69$2.70104.42K
Oct 15, 2026$2.66$2.80$2.66$2.75107K
Oct 14, 2026$2.62$2.79$2.55$2.66134.33K
Oct 13, 2026$2.71$2.8655$2.5301$2.59574.62K
Oct 12, 2026$2.77$2.80$2.57$2.7398.19K
Oct 9, 2026$2.54$2.8326$2.501$2.78165.85K
Oct 8, 2026$2.72$2.75$2.52$2.53255.56K
Oct 7, 2026$2.98$2.98$2.65$2.71228.76K
Oct 6, 2026$2.95$3.07$2.9168$2.99173.71K
Oct 5, 2026$3.00$3.13$2.8839$2.92197.3K
Oct 2, 2026$3.06$3.18$2.95$2.99234.93K
Oct 1, 2026$3.37$3.3845$3.05$3.06161.06K
Sep 30, 2026$3.28$3.47$3.19$3.405131.72K
Sep 29, 2026$3.35$3.50$3.12$3.30180.91K

Latest NTHI news

The latest Smart Investors Daily articles mentioning NTHI.

Stock researchCompany · Overview

NTHI research

Overview

Company profile and research snapshot.

Company profile

NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
NTHI recent ratings
DateFirmRatingTarget
Sep 24, 2026Roth CapitalBuy—
Sep 8, 2026BTIGBuy—
May 26, 2026BTIGBuy—
May 19, 2026Alliance Global PartnersBuy—
May 18, 2026Maxim GroupBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 21, 2026

NeOnc's Brain Cancer Efforts Bring Hope as FDA Meeting Approaches

Compassionate care for children in Abu Dhabi, a new research MoU and a senior banking appointment add momentum to NeOnc's development storyHouston, Texas--(Newsfile Corp. - October 21, 2026) - As NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) prepares for an upcoming FDA meeting, its work in Abu Dhabi is bringing that human side of biotechnology into focus.Technology today can feel like magic. For families confronting a child's brain cancer, the hope that medical science might accomplish...

Yahoo · Oct 21, 2026

NeOnc Technologies and the Department of Health – Abu Dhabi Sign MoU to Advance Brain Cancer Research and Proposed Clinical Collaboration

Proposed collaboration covers scientific exchange, specialist training and real-world evidence, alongside assessment of clinical trial opportunities and a potential regional presence for NeOnc in Abu Dhabi Two children in Abu Dhabi are receiving investigational NEO100 through NeOnc’s Compassionate Care program, with a third expected this week CALABASAS, Calif. and ABU DHABI, United Arab Emirates, Oct. 21, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “

Yahoo · Oct 16, 2026

NeOnc's Most Challenging Test Yet: Compassionate-Use Update Puts NEO100's Potential in Focus

Pediatric Case, Abu Dhabi Expansion and Board Appointment Highlight a Broader Development StrategyHouston, Texas--(Newsfile Corp. - October 16, 2026) - NeOnc Technologies Holdings (NASDAQ: NTHI) is confronting one of the most consequential tests of its investigational brain-cancer platform as it pursues treatment options for patients facing some of the most difficult challenges in neuro-oncology. The company recently reported an early clinical update involving a critically ill three-year-old boy

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By